Primary pleural epithelioid hemangioendothelioma: case report and review of the literature
Daniele Lavacchi, Luca Voltolini, Camilla Eva Comin, Francesca Mazzoni, Giacomo Giulio Baldi, Vittorio Briganti, Silvia Luvara, Stefano Bongiolatti and Lorenzo Antonuzzo.

Introduction
Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular sarcoma with an unpredictable clinical behavior. Pleural EHEs have been associated with poor response to treatment and reduced survival. To date, no standard treatment for EHE is available. Here we report the case of a 53-year-old man who underwent radical surgery for a symptomatic primary pleural EHE. Clinical presentation was characterized by chronic pain in the left hemithorax with transitory flare, anemia, weight loss and progressive worsening of clinical conditions. After surgery, he resumed active life and normal daily activities and, at 8 months, 18F-FDG PET and computed tomography scan showed no radiological evidence of recurrent disease. Clinical signs of this rare disease, histological features, imaging findings and functional imaging are discussed. We also report a summary of other cases with resected pleural EHE and we briefly review the role of chemotherapeutic, immunomodulatory and antiangiogenic drugs for advanced disease. Anti-Cancer Drugs 32: 1131–1137 Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords: antiangiogenic drugs, epithelioid hemangioendothelioma, extrapleural pneumonectomy, immunomodulatory drugs, pleural EHE

Case report
In April 2020, a 53-year-old Caucasian man came to our hospital, presenting chronic pain in the left hemithorax with transitory flare, particularly in the evening. A diagnosis of pleurisy was initially suspected and the patient received antibiotics, corticosteroids and no steroid anti-inflammatory drugs with low improvement.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
| Authors            | Age and sex | Symptoms at presentation | Signs at presentation                   | Diagnosis                                                                 | Surgery                                | Other treatments                                                                 | Median DFS from surgery (months) | Median OS from surgery (months) |
|-------------------|-------------|--------------------------|-----------------------------------------|---------------------------------------------------------------------------|----------------------------------------|---------------------------------------------------------------------------------|--------------------------------|-----------------------------|
| Lee et al. [3]    | 31 years, F | Upper back and radiating, bilateral shoulder pain. | Right nodular pleural thickening with several foci, and bone metastases. | Thoracscopy: multiple scattered subpleural whitish-tan plaques; intraparenchymal growth. | Wedge resection of the right lower lobe of the lung | Palliative radiotherapy on the spine and chemotherapy with Adriamycin as first-line treatment followed by mesna-doxorubicin-fosfamide-dacarbazine as second-line treatment | ≈10                           | ≈10                         |
| Crotty et al. [4] | 4 males with median age of 62 years | Chest pain, dyspnea, productive cough, fever and weight loss | Moderate-sized pleural effusions with smooth and nodular pleural thickening. | Three patients underwent open thoracotomy with pleural decortication. | Three out of four patients underwent open thoracotomy with pleural stripping and decortication procedures, for diagnostic purposes and palliation. | Not specified                                                          | ≈10                           | ≈10                         |
| Kim et al. [11]   | 46 years, F | Right-sided chest discomfort and cough. | Right-sided pleural effusion | Diagnostic thoracotomy: thick peel involving the pleural surfaces. | Thoracocentesis: negative findings in one patient and positive findings for undifferentiated malignancy in another one. | Initial decortication and visceral pleurectomy. Subsequent complete pleurectomy with cybriduction to minimal disease. Pleural decortication | Postoperative chemotherapy with carboplatin and etoposide for residual disease | ≈30                           | ≈30                         |
| Saqi et al. [12]  | 37 years, M | Progressive dyspnea and right-sided pleuritic chest pain | Right-sided pleural effusion | Thoracocentesis and pleural decortication. | | | Postoperative carboplatin, etoposide, and bevacizumab for one course | ≈30                           | ≈30                         |
| Al-Shraim et al. [13] | 51 years, M | Dry cough, shortness of breath | Left-sided pleural effusion. Pleural thickening forming a nodular mass | Pleuroscopy: results interpreted as malignant mesothelioma, undifferentiated, small cell type. Correct diagnosis came from histological review. | Left lung decortication and resection of the pleural tumor | Interferon                                                        | NR >24                        | ≈30                         |
| Yu et al. [14]    | 39 years, F | Progressive dyspnea | Mass lesion in the left thorax invading the pericardium and compressing the myocardium. | Thoracocentesis and pericardiocentesis: bloody exudative effusion. Fine needle aspiration: atypical inflammatory cells. Sternotomy: parenchymatous mass contiguous with a calcified mass on the left pleura. | Thoracocentesis and pleural decortication. | Thoracocentesis and pleural decortication. | Postoperative chemotherapy with carboplatin and etoposide | >14                           | >14                         |
| Chou et al. [15]  | 42 years, M | Chest pain and productive cough | Pleural effusion and irregular thickness of the left pleura with small nodularities. | Pleural biopsy. | | | Pleuroscopy. Radiotherapy and chemotherapy for recurrent disease. | 5                            | ≈14                         |
|                  | 27 years, M | Dry cough, hoarseness, and chest tenderness | Pleural mass and left hemidiaphragm paralysis. | Partial pleurectomy: fibrotic lesion measuring 3.7 x 2.0 x 2.0 cm in size in the left pleura of the lung apex. | | | Postoperative radiotherapy and subsequent pleurectomy for recurrent disease. | NR <18                        | ≈14                         |
| Bevelaqua et al. [16] | 22 years, M | Fever | Right pleural effusion | Thoracocentesis: serosanguineous exudative effusion negative for malignancy. Exploratory thoracotomy: lobulated hemorrhagic mass originating from the diaphragm. | | | Excision of the mass, one-third of the diaphragm, a portion of the right lower lobe, and associated parietal pleura. | NR                            | NR                         |
| Apolínário et al. [17] | 47 years, M | Chest pain and dyspnea | Left pleural effusion | Cytological examination: negative for malignancy. Bronchopleuroscopy: negative for malignancy. Thoracocopy with pleural biopsy: severe adhesion in the thoracic cavity. | | | Postoperative doxorubicin | NR                            | ≈14                         |
| Takenaka et al. [18] | 62 years, M | Right chest pain and dyspnea | Diffuse pleural thickening with uptake at FDG-PET and right pleural effusion | Extensive pleural pneumonectomy. | | | Pazopanib for recurrent disease | 1 ≈3.5                        | ≈14                         |
The patient was then hospitalized due to a quick pain worsening. A computed tomography (CT) scan showed a very slight left pleural effusion, multiple bilateral ground glass pulmonary nodules with ‘tree-in-bud’ pattern and an inflammatory thickening in the left lower lobe. Thus, bronchoscopy with transbronchial needle aspiration was performed with negative results. In May 2020, an 18F-FDG PET showed a mild diffuse tracer uptake in the left pleura (Fig. 1). A few weeks later, the patient experienced a progressive worsening of pain requiring high doses of opioids. The clinical conditions were progressively getting worse and he started to develop systemic symptoms like severe fatigue, anemia, weight loss and uncontrolled pain. A new CT scan showed a left-sided pleural effusion with diffuse pleural thickening (Fig. 2). He underwent pleuroscopy, which revealed irregular thickness of the left pleura. Biopsies from parietal and diaphragmatic pleura showed an infiltrating neoplastic proliferation consisting of nests and cords of epithelioid cells having glassy eosinophilic cytoplasm and oval vesicular nuclei. Cytoplasmic vacuoles were evident. Immunohistochemistry showed diffuse positivity for CD31, ERG, CD34 and CAMTA1 and negative staining for cytokeratins AE1/AE3, STAT-6, TTF-1 and P40. The diagnosis of EHE was assessed. (Fig. 3) Due to the low response rate to chemotherapy in this disease, the worse prognosis determined by pleural involvement and the need for rapid symptom control, in July 2020, we discussed in a multidisciplinary fashion a surgical treatment in order to better symptoms control and to improve quality of life. The patient underwent extrapleural pneumonectomy in July 2020 (Fig. 4). On surgical specimen, histological examination showed pleural, lung, pericardial, diaphragmatic and peritoneal involvement. In the following months, the patient obtained excellent pain relief with progressive reduction of the opioid dose. He resumed active life and normal daily activities regaining the lost weight. Eight months after surgery, in March 2021, 18F-FDG PET and CT scans showed no radiological evidence of recurrent disease, although the patient had a slow worsening of painful symptoms.

**Surgical procedure**

Surgery consisted in a left extrapleural pneumonectomy (Fig. 4). A first standard left posterolateral thoracotomy was performed along the course of the sixth rib. A subperiosteal resection of the sixth rib was then performed to provide wider exposure and to readily facilitate the initiation of the extrapleural dissection. Once the extrapleural plane was established the entire lateral dissection, both
superiorly and inferiorly was done bluntly with a dissecting hand with subsequent placement of a chest retractor. Dissection then proceeded anteriorly both superiorly toward the apex of the chest and inferiorly toward the diaphragm using blunt and sharp techniques. Care was taken at the apex to avoid injury to the subclavian artery and vein and medially to preserve the internal mammary artery and vein dividing small adhesions, staying close to the pleural plane in the extrapleural fat. As dissection continued along the mediastinum, care was taken to avoid injury to the left vagus and left recurrent laryngeal nerve. The dissection continued posteriorly along the aorta, with particular attention to enter the correct plane in the preaortic region in order to avoid avulsing the intercostal vessels. Dissection was carried extrapleurally until the left main bronchus was clearly identified. Once the specimen has been circumferentially dissected from the chest wall, we performed a second lateral thoracotomy; entering the pleural space through the eighth intercostal space and move the rib spreader to this interspace in order to provide better exposure to the diaphragm, after having continued the extrapleural dissection into the costophrenic sulcus. The diaphragm was incised at its anterior margin and extended in a circumferential fashion laterally and posteriorly with care being taken to avoid injury to the left vagus nerve and the esophagus at the hiatus and to preserve the underlying peritoneum which was swept away from the diaphragm with the aid of a sponge stick. The diaphragmatic muscle fibers were divided with cautery or simply avulsed from their insertion. The retractor was then moved back to the fifth intercostal space and the pericardium was entered anteroinferiorly and the pulmonary vessels were identified. The left main pulmonary artery was divided in its extrapericardial, extrapleural position using an endoscopic linear stapling device. The upper and lower left pulmonary veins were encircled within the pericardium and individually divided with a vascular stapling device. The pericardial resection was then completed posteriorly. Finally, the left main bronchus was dissected back to the carina and divided flush with the carina with a bronchial stapler, after having retracted the double lumen endotracheal tube in trachea. So doing, the left bronchial stump retracted well back into the mediastinum and it was considered unnecessary for its buttressing. The surgical specimen was removed and a systematic lymph node dissection

Preoperative contrast-enhanced CT scan images on axial and coronal planes (a) and postoperative contrast-enhanced CT scan image on coronal plane (b).
completed the resectional phase. The entire hemithorax was inspected for hemostasis. Reconstruction of the diaphragm was then carried out, moving the retractor to the lower intercostal incision. The diaphragm was reconstructed with a 2-mm thick PTFE patch (20 × 30 cm) secured to the chest wall laterally, anteriorly and posteriorly by the placement of interrupted monofilament sutures. Medially, the diaphragmatic path was sewn to the diaphragmatic edge of the divided pericardium and to the fibers of the crus. Then the pericardium was reconstructed with a 0.1-mm PTFE pericardial patch using a nonabsorbable monofilament suture. Fenestrations were created in the patch to prevent tamponade. Inferiorly, the patch was secured to the diaphragmatic patch with several interrupted monofilament sutures. The pleural space was irrigated with 2 liters of aqueous betadine solution. The chest was closed over a single basal drainage tube that had been connected to a balanced drain. The recovery was uneventful and the patient was discharged home in the 12th postoperative day.

Discussion

Diagnosis and treatment of EHE remain a challenge. A watchful-waiting approach until disease progression could be a reasonable option mostly in patients with multifocal and/or multicentric presentation without symptoms and/or serosal effusions. Some authors indeed reported long-lasting stable disease (SD) with observation only or even a spontaneous regression of metastatic lesions [1,8,20]. Although no standard treatment has been established, complete surgical excision should be considered in localized disease. In a case series of patients (n = 32) treated at The Royal Marsden Hospital, 20% of whom underwent surgical resection, surgery and liver only disease were the two main factors associated with long-term survival outcomes [21]. Unfortunately, more than two-thirds of patients had a multifocal/multicentric disease, no longer suitable for local treatments. In these cases, medical therapy has rarely been associated with significant clinical benefits. Overall, the response rate was low with chemotherapy, but sometimes an improvement in symptoms was observed, including relief from pleuritic pain or irritable cough. To date paclitaxel, gemcitabine or anthracycline-based combinations, mostly used in angiosarcoma, are the most commonly used cytotoxic

Histological examination. (a) Hematoxylin–eosin showing neoplastic proliferation consisting of nests and cords of epithelioid cells having glassy eosinophilic cytoplasm and oval vesicular nuclei (10×); widespread and intense positivity on immunohistochemistry for (b) CD31 (10×), (c) ERG (10×), (d) CAMTA1 (10×).
agents [19,21–24]. Anecdotal responses to other chemotherapeutic agents (i.e. carboplatin etoposide and cyclophosphamide) were reported, but evidence is limited and results are controversial [19,25,26].

Immunomodulatory and antiangiogenic drugs seem to be the most promising treatment options, but evidence derives primarily from retrospective case series and case reports. Interferon and thalidomide were initially used with conflicting results [19,24,27,28]. A remarkable benefit was observed with sirolimus in a series of patients with progressive EHE treated within the Italian Rare Cancer Network. Sirolimus was demonstrated to be feasible and effective in terms of disease control [6]. In a recent update of this series including 37 patients evaluable for response, disease control rate (DCR) was 86.5% with 4 patients who experienced a partial response (PR) (ORR 10.8%). Median progression-free survival (PFS) was 13 months and median overall survival (OS) was 18.8 months. This study confirmed pleural effusion as a predictor of poor prognosis, with median PFS of 4.8 months ($P < 0.0001$) and OS of 10.6 months ($P < 0.0001$) [29].

Given the vascular origin of EHE, the antiangiogenic strategy was considered a rational approach and the activity of several drugs has been studied in the past. The French Sarcoma Group conducted a phase II trial with sorafenib in 15 patients with EHE, of whom 10 in first-line treatment and 5 in subsequent lines. Only one patient in this group had a primary pleural EHE. Sorafenib showed a modest clinical activity with 9-month PFS rate of 30.7% and 2-year OS rate of 26%. Two PR were reported [30]. Other antiangiogenics including axitinib, sunitinib, pazopanib and sunitinib were used in a retrospective case series of Yousefi et al. Although no responses were observed in pretreated patients, disease stabilization and symptom control were reported [21]. Prolonged SD with the use of pazopanib was also described in two case reports [31,32], with PFS of 8 years and 2 years, respectively. In 2009, pazopanib received Food and Drug Administration and than European Medicines Agency approval for the treatment of pretreated advanced soft tissue sarcoma, including EHE [33]. A retrospective study collecting data from patients included in the European Organization for Research and Treatment of Cancer (EORTC) phase II and III trials or treated in clinical practice at EORTC centers was conducted. Among patients with EHE, pazopanib provided a DCR of 60% (6 out of 10 patients) with a median PFS of 26.3 months; [34] conversely the recently published observational retrospective case series study within the World Sarcoma Network showed no responses in 12 patients treated with pazopanib with a median PFS and a median OS of 2.9 and 8.5 months, respectively [24]. Bevacizumab has also shown clinical activity in the treatment of vascular sarcoma. In a multicenter phase II study including 7 patients with advanced EHE treated with bevacizumab, 2 patients achieved a PR and 4 an SD (ORR of 29% and DCR of 86%) [35].

Although our patient had several negative prognostic factors as pleuro-pulmonary disease, pleural effusion and systemic symptoms, he greatly benefited from palliative surgery. Nevertheless, the management of patients with pleural EHE remains challenging and extended palliative surgery, as in our case, cannot be routinely proposed. Only a few cases of patients treated with palliative surgery for pleural EHE have been reported (Table 1). Overall, these patients had different clinical courses and survival after surgery ranged from a few months to more than 2 years. Therefore, given the unpredictable clinical behavior of the disease, after a multidisciplinary discussion in sarcoma tumor board, palliative surgery could be an option in selected patients in centers with high volume and expertise in soft tissue sarcoma.

Acknowledgements

Conflicts of interest
There are no conflicts of interest.

References

1 Kitaichi M, Nagai S, Nishimura K, Itoh H, Asamoto H, Izumi T, Dail DH. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. *Eur Respir J* 1998; 12:89–96.
Primary pleural epithelioid hemangioendothelioma Lavacchi et al. 1137

2 Rubin BP, Deyrup AT, Doyle LA. Epithelioid haemangioendothelioma. In: World Health Organization (WHO) Classification of Soft Tissue and Bone Tumours. 5th ed. Lyon: International Agency for Research on Cancer (IARC); 2020. pp. 172–175.

3 Lee YJ, Chung MJ, Jeong KC, Hahn CH, Hong KP, Kim YJ, Kim YT. Pleural epithelioid hemangioendothelioma. *Yonsei Med J* 2008; 49:1036–1040.

4 Crotty EJ, McAdams HP, Erasmus JJ, Sporn TA, Roggli VL. Epithelioid hemangioendothelioma of the pleura: clinical and radiologic features. *AJR* 2002; 178:1545–1549.

5 Anderson T, Zhang L, Hameed M, Rusch V, Travis WD, Antonescu CR. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. *Am J Surg Pathol* 2015; 39:132–139.

6 Stacciotti S, Provenzano S, Dagraga G, Negri T, Brich S, Basso U, et al. Sipilimun in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian Rare Cancer Network Database. *Ann Surg Oncol* 2016; 23:2735–2744.

7 Simeone N, Baldi GG, Frezza AM, et al. Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): a retrospective analysis within the Italian Rare Tumor Network (RTR). *J Clin Oncol* 2019; 37 (15_Suppl):11065–11065.

8 Rosenbaum E, Jadea B, Xu Z, Zhang L, Agaram NP, Travis W, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. *Mod Pathol* 2020; 33:591–602.

9 Frezza AM, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, et al. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network. *ESMO Open* 2021; 6:100083.

10 Bagan P, Hassan M, Le Pimpec Barthes F, Peyrand S, Souilamas R, et al. Activity of sirolimus in advanced epithelioid hemangioendothelioma: a review of the literature. *Ann Thorac Surg* 2008; 82:2010–2013.

11 Kim EA, Lele SM, Lackner RP. Primary pleural epithelioid hemangioendothelioma. *Ann Thorac Surg* 2011; 91:301–302.

12 Saqi A, Nisbet L, Gagneja P, Leslie KO. Primary pleural epithelioid hemangioendothelioma with rhodoblast phenotype: report and review of the literature. *Diagn Cytopathol* 2007; 35:203–208.

13 Al-Shraim M, Mahboub B, Noligan PC, Chamberlain D, Ghazarian D, et al. Primary pleural epithelioid haemangioendothelioma with metastases to the skin. A case report and literature review. *J Clin Pathol* 2005; 58:107–109.

14 Yu L, Gu T, Xiu Z, Shi E, Zhao X. Primary pleural epithelioid haemangioendothelioma comprising the myocardium. *J Card Surg* 2013; 28:266–268.

15 Chou YY, Hsieh YS, Wu CC, et al. Epithelioid hemangioendotheliomas of the lung and pleura: report of three cases. *Form J Surg* 2011; 44:163–167.

16 Bevelacqua FA, Valensi Q, Roggll VL. Epithelioid hemangioendothelioma. A rare tumor with variable prognosis presenting as a pleural effusion. *Chest* 1988; 93:665–666.

17 Apolinarlo D, Silva J, Loureiro Al, Noya R, Carvalho L. Beyond a pleural effusion: primary pleuropulmonary sarcomas and the challenge of diagnosis. *Rev Port Pneumol* (2016) 2016; 22:299–299.

18 Takenaka M, Ichiki Y, Nabe Y, Tsuda Y, Kuwata T, Chikaishi Y, et al. Difficulty of treatment for pleural epithelioid hemangioendothelioma: a report of a case. *Gen Thorac Cardiovasc Surg* 2020; 68:190–193.

19 Ye B, Li W, Feng J, Shi JX, Chen Y, Han BH. Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: report of three cases and review of the literature. *Oncol Lett* 2013; 5:1491–1496.

20 Otrock ZK, Al-Kutoubi A, Kattar MM, Zaatar G, Soweid A. Spontaneous complete regression of hepatic epithelioid haemangioendothelioma. *Lancet Oncol* 2006; 7:439–444.

21 Yusuf N, Manuzzo M, Judson I, Al-Muderis O, Fisher C, Benson C. Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. *Anticancer Res* 2015; 35:473–480.

22 Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly pacitaxel for unresectable angiosarcoma: the ANGIO-TAX Study. *J Clin Oncol* 2008; 26:5269–5274.

23 Cioffi A, Italiano A, Penel N, et al. Metastatic epithelioid hemangioendothelioma (EHE): role of systemic therapy and survival. *J Clin Oncol* 2011; 29 (15_Suppl):10079–10079.

24 Frezza AM, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, et al. Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of the literature. *Cancer Med* 2021; 10:2645–2659.

25 Pinet C, Magnan A, Garbe L, Payan MJ, Vervloet D. Aggressive form of pleural epithelioid haemangioendothelioma: complete response after chemotherapy. *Eur Respir J* 1999; 14:237–238.

26 Lakkis Z, Kim S, Delabrouse E, Jary M, Nguyen T, Mantion G, et al. Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma. *J Hepatol* 2013; 58:1254–1257.

27 Kayler LK, Meron RM, Arenas JD, Magee JC, Campbell DA, Rudich SM, Punch JD. Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. *Transplantation* 2002; 74:128–130.

28 Salech F, Valderrama S, Nervi B, Rodriguez JC, Oksenberg D, Koch A, et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. *Ann Hepatol* 2011; 10:99–102.

29 Stacciotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, et al. Activity of sirolimus in patients with progressive epithelioid haemangioendothelioma: a case-series analysis within the Italian Rare Cancer Network. *Cancer* 2021; 127:569–576.

30 Chevreau C, Le Cesne A, Ray-Coquard I, Italiano A, Cioffi A, Isambert N, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GFS/GETO). *Cancer* 2013; 119:2639–2644.

31 Bally O, Tassy L, Richoud B, Decouvelaere AV, Blay JY, Derbel O. Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. *Clin Sarcoma Res* 2015; 5:12.

32 Semenisty V, Naroditsky I, Keidar Z, Bar-Sela G. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options. *BMC Cancer* 2015; 15:402.

33 van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012; 379:1879–1895.

34 Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, et al. Pazopanib for advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. *Acta Oncol* 2017; 56:98–92.

35 Aguilnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. *Ann Oncol* 2013; 24:257–263.